Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753722 | 0.87 | FFAR1 (0.49) | SLC1A1PPARAPPARGFFAR1CETP | |
| SCHEMBL5749740 | 0.86 | SLC1A1 (0.43) | SLC1A1PPARAPPARGFFAR1ALDH1A1 | |
| SCHEMBL5753245 | 0.85 | SLC1A1 (0.44) | SLC1A1PPARAPPARGCETP | |
| SCHEMBL5754855 | 0.84 | SLC1A1 (0.48) | SLC1A1PPARAPPARGALDH1A1KDM4E | |
| SCHEMBL5750291 | 0.83 | TAAR1 (0.43) | PPARAPPARGNPSR1ALDH1A1KDM4E | |
| SCHEMBL5752432 | 0.83 | MEN1 (0.44) | SLC1A1PPARAPPARGNPSR1SMN1; SMN2 | |
| SCHEMBL5748762 | 0.83 | CETP (0.46) | SLC1A1PPARAPPARGCETP | |
| SCHEMBL5752306 | 0.80 | HTR1A (0.44) | SLC1A1PPARAPPARGNPSR1ALDH1A1 | |
| SCHEMBL5752844 | 0.79 | SLC1A1 (0.45) | SLC1A1PPARAPPARGALDH1A1KDM4E | |
| SCHEMBL5751805 | 0.78 | SLC1A1 (0.47) | SLC1A1PPARAPPARGNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | SLC1A1 343/4885PPARA 708/4885PPARG 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.